

# Teaching genomics

Kelly Ormond, MS, LCGC  
Stanford University  
California, USA



## From then to now...




- Rare, serious
- Mendelian
- Highly penetrant
- Few genetic tests
- Based on FHx or ethnicity

- Thousands of genetic tests
- Testing panels
- Still start with a differential dx, triage testing till a diagnosis found
- Predictive testing often available
- Slow clinical incorporation in many areas (e.g. GWAs, pharmacogenomics) d/t limited evidence base

- WES/WGS as a technique and a test
- Analytic and clinical validity
- Often used after other tests negative
- 'Incidental' findings

- Few GCs or geneticists
- Mostly practicing in pediatrics or OB

- ~3700 GCs and 1400 geneticists certified in US since 1982
- Expanded into many specialties (oncology, cardio, neuro, psych, etc.)
- Lab and Industry GCs
- Growing international presence in clinical genetics



### DTC Genomic Testing

**Best Inventions of 2008**  
The Retail DNA Test

PATHWAY GENOMICS<sup>®</sup>

deCODE genetics

23andMe

Navigenics

### What if your 'patient' is Steve Quake, and he sequences his own genome?

**Clinical assessment incorporating a personal genome**

Luca Adlroth, Axel Birba, Matthew T Wheeler, Bing Chen, Teri Klein, Frederick E Dewey, Just T Dudley, Kelly Ormond, Aleksandra Prokhor, Alexander A Morgan, Dmitry Potkin, Norman Nadj, Lonneke Hulsbergen, Li Gong, Laura M Hoadley, Dan S Karlin, Caroline F Thurn, Brian Sengler, John M Havel, Mark Wronski, Sarah Grogan, Ryan Whaley, Joshua W Kovacs, Michael J Chen, Joseph V Thakur, Abraham M Koushanfar, Alexander Wolf, Zoran, George M Church, Henry T Condy, Stephen J Quake, Ross B Altman

**Summary**  
Background: The cost of genomic information has fallen steeply, but the clinical translation of genetic risk estimates remains unclear. We aimed to undertake an integrated analysis of a complete human genome in a clinical context.

### What am I supposed to do with this?

### NCBI's ClinVar

**ClinVar: public archive of relationships among sequence variation and human phenotype**

Melissa J. Landrum, Jennifer M. Lee, George R. Riley, Wonhee Jung, Wendy S. Rubinstein, Deanna M. Church and Donna R. Maglott

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, 8600 Rockville Pike, Bethesda, MD 20894, USA

### HGMDB<sup>®</sup> Human Gene Mutation Database

Start Free Trial

CETR Clinical and Functional Translation of CETR

**Breast Cancer Information Core**  
An Open Access On-Line Breast Cancer Mutation Data Base  
An International Collaborative Effort hosted by NHGRI

LOVD<sup>3</sup> Leiden Open Variation Database

dbGaP GENOTYPE and PHENOTYPE

OMIM

GENEReviews

LS&GT

### The future: WGS on healthy individuals

**Clinical assessment incorporating a personal genome**

Luca Adlroth, Axel Birba, Matthew T Wheeler, Bing Chen, Teri Klein, Frederick E Dewey, Just T Dudley, Kelly Ormond, Aleksandra Prokhor, Alexander A Morgan, Dmitry Potkin, Norman Nadj, Lonneke Hulsbergen, Li Gong, Laura M Hoadley, Dan S Karlin, Caroline F Thurn, Brian Sengler, John M Havel, Mark Wronski, Sarah Grogan, Ryan Whaley, Joshua W Kovacs, Michael J Chen, Joseph V Thakur, Abraham M Koushanfar, Alexander Wolf, Zoran, George M Church, Henry T Condy, Stephen J Quake, Ross B Altman

**Summary**  
Background: The cost of genomic information has fallen steeply, but the clinical translation of genetic risk estimates remains unclear. We aimed to undertake an integrated analysis of a complete human genome in a clinical context.

**Challenges in the clinical application of whole-genome sequencing**

Kelly E Ormond, Matthew T Wheeler, Lonneke Hulsbergen, Teri E Klein, Axel J Birba, Ross B Altman, Ewan A Ashley, Henry T Condy

As the cost of sequencing the human genome falls, or more serious diseases. For example, a patient could...

**Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence**

Frederick E Dewey<sup>1</sup>, Rong Chen<sup>1</sup>, Sergio P. Cordero<sup>1</sup>, Kelly E. Ormond<sup>1,2</sup>, Colleen Calasho<sup>1</sup>, Konrad J. Karczewski<sup>1,3</sup>, Michelle White-Carrillo<sup>1</sup>, Matthew T. Wheeler<sup>1</sup>, Just T. Dudley<sup>1,4</sup>, Jake R. Berrett<sup>1</sup>, Oscar E. Conroy<sup>1</sup>, Joshua W. Kovacs<sup>1</sup>, Mark Wronski<sup>1</sup>, Kaitlin Sengler<sup>1,5</sup>, Li Gong<sup>1</sup>, Caroline F. Thurn<sup>1</sup>, Joan M. Haber<sup>1</sup>, Emilio Capriotti<sup>1</sup>, Sean P. Dewitt<sup>1</sup>, Aleksandra Prokhor<sup>1</sup>, Anna West<sup>1</sup>, Joseph W. Thakur<sup>1</sup>, Elizabeth P. Ruff<sup>1</sup>, Alexander W. Zaranek<sup>1</sup>, Heidi L. Rubin<sup>1</sup>, George M. Church<sup>1</sup>, John S. Wiley<sup>1</sup>, Curtis D. Bustamante<sup>1</sup>, Michael Snyder<sup>1</sup>, Russ B. Altman<sup>1,6</sup>, Teri E. Klein<sup>1</sup>, Axel J. Birba<sup>1</sup>, Ewan A. Ashley<sup>1,7</sup>

**Molecular Genetics & Genomic Medicine** Open Access

INVITED COMMENTARY

**From genetic counseling to “genomic counseling”**

Kelly E. Ormond  
Department of Genetics and Stanford Center for Biomedical Ethics, Stanford University School of Medicine, Stanford, CA, 94305-5208

J Genet Counsel  
DOI 10.1007/s10897-014-9688-4

**NEXT GENERATION GENETIC COUNSELING**

**Teaching Genomic Counseling: Preparing the Genetic Counseling Workforce for the Genomic Era**

Gillian W. Hosker · Kelly E. Ormond · Kevin Sweet · Barbara B. Biesecker

Received: 29 June 2013 / Accepted: 9 January 2014  
© Springer Science+Business Media New York (Outside the USA) 2014

## What were programs teaching in 2011/2012?

Profino et al.

682

**Table 1** Integration of genomics into training program curricula of 17 genetic counseling training programs, based on survey data

	Status in training programs, n (%)			Formal curriculum, n (%)		Informal curriculum, n (%)			
	Currently taught	Under development	Will not be taught	Course lectures	Required guest lectures	Optional guest lectures	Professional meetings	Clinical rotations	Journal clubs
Genomic technologies	15 (88 %)	2 (12 %)	0 (0 %)	17 (100 %)	8 (47 %)	5 (29 %)	11 (65 %)	8 (47 %)	15 (88 %)
GWAS	14 (82 %)	2 (12 %)	1 (6 %)	15 (88 %)	5 (29 %)	5 (29 %)	9 (53 %)	7 (41 %)	11 (65 %)
Complex disease genetics	15 (88 %)	1 (6 %)	1 (6 %)	15 (88 %)	8 (47 %)	7 (41 %)	8 (47 %)	10 (59 %)	11 (65 %)
DTCSNP*	11 (73 %)	4 (27 %)	0 (0 %)	10 (59 %)	4 (24 %)	5 (29 %)	10 (59 %)	4 (24 %)	10 (59 %)
Pharmacogenomics*	13 (81 %)	3 (19 %)	0 (0 %)	14 (82 %)	3 (18 %)	3 (18 %)	8 (47 %)	2 (12 %)	7 (41 %)
Genomic counseling	12 (71 %)	5 (29 %)	0 (0 %)	13 (76 %)	5 (29 %)	3 (18 %)	11 (65 %)	11 (65 %)	9 (53 %)

Topics are listed here in the order that they were listed on the survey  
 \*Only 15 participants responded regarding DTCSNP; therefore, the percentage is n/15 for this topic  
 †Only 16 participants responded regarding pharmacogenomics; therefore, the percentage is n/16 for this topic


## Ways we do it

- Molecular genetics curriculum
- Informal learning (journal clubs, department talks, grand rounds)
- Role modeling involvement
- Variant interpretation rotation – required
- Research project focus

## Testing ‘Panels’

- **Chip based approaches to examine a range of genes**
  - Examine common mutations vs. Sequencing based technologies
- **Especially helpful when a disorder has significant locus heterogeneity that cannot be clinically differentiated or have significant overlap**
- **Experienced clinicians may find ordering targeted testing more sensitive and specific**

- **Currently available examples**
  - Nonsyndromic hearing loss
  - Cardiology (cardiomyopathy, arrhythmias, other CV disorders)
  - RASopathies
  - Mitochondrial disease
  - Cancers
  - Autism spectrum
  - Severe combined immunodeficiency
  - X linked intellectual disability
  - Carrier testing



**RCM**

### Deleterious mutations in disease genes related to clinical phenotype

Sample of eye T and color I and color

Date Ordered: Date Reported:

### VUS in disease genes related to clinical phenotype

1. Deleterious mutations in disease genes related to clinical phenotype (Table 1)

2. Variant of unknown clinical significance in disease genes related to clinical phenotype (clinical status not discussed below, see Table 2 for the complete list)

### Medically actionable mutations (or even VUS?) in disease genes unrelated to clinical phenotype

### Carrier status for recessive Mendelian disorders

### Pharmacogenetic results

## Variant interpretation

- Required since graduating class of 2013
- Students complete 20-100 variants
- Learn about underlying bioinformatics, databases for variant interpretation
- ‘walk through a genome’

## Getting up to speed interpreting genomes

- **Technology:**
  - Limitations of various platforms, areas of the genome
  - General principles: base calling, alignment, error rates
- **Classic concepts of inheritance and the impact of mutation types**
- **Bioinformatics assumptions and limitations**
  - Conservation modeling
  - Inheritance modeling
  - Pipeline assumptions
  - Variant and splice site predictors
- **Manual processes and available databases**
  - OMIM, HGMD, ClinVar, dbSNP, 1000 genomes, LOVD, etc...

Hooker et al. (JGC, 2014)

## 'Rotation' goals

- **At the end of this rotation, you will understand:**
- The different contexts in which WGS and WES are currently being applied in a research setting
- How to research and classify potentially disease causing variants found through sequencing technologies
- The differences in approaches to variant identification and curation for healthy individuals as opposed to individuals with a likely genetic disease
- Ethical and counseling issues involved in whole-genome sequencing including special considerations for consent, privacy, information storage and updates, genomic literacy and return of results
- **You will be expected to be able to:**
- Demonstrate knowledge of genome sequencing technology and the bioinformatics pipelines used to call and classify the variants
- Develop expertise in using various variant annotation genome databases including NHLBI ESP, ExAC, 1000Genomes, ClinVar, HGMD, dbSNP, UCSF, Polyphen, SIFT, mutation taster, and various locus specific databases to clinically interpret variants
- Demonstrate knowledge of various considerations involved in consenting individuals for WES/WGS in a research environment
- Go through the process of analyzing a healthy participant exome for variants likely to be medically relevant, and return results back to the participant

## Balancing many curricular needs

### Domain I: Genetics Expertise and Analysis

1. Demonstrate and utilize a depth and breadth of understanding and knowledge of genetics and genomics core concepts and principles.
2. Integrate knowledge of psychosocial aspects of conditions with a genetic component to promote client well-being.
3. Construct relevant, targeted and comprehensive personal and family histories and pedigrees.
4. Identify, assess, facilitate, and integrate genetic testing options in genetic counseling practice.
5. Assess individuals' and their relatives' probability of conditions with a genetic component or carrier status based on their pedigree, test results, and other pertinent information.
6. Demonstrate the skills necessary to successfully manage genetic counseling case.
7. Critically assess genetic/genomic, medical and social science literature and information.


### Domain II: Education

8. Understand how to adapt genetic counseling skills for varied service delivery models.
9. Apply genetic counseling skills in a culturally sensitive and respectful manner to all clients.
10. Effectively educate clients about a wide range of genetic and genomic information based on their needs, their characteristics and the circumstances of the consultation.

### Domain III: Professional Development & Practice

11. Write concise and understandable clinical and research reports on the outcomes of varying educational engagements.
12. Effectively give a presentation on genetics, genomics and genetic counseling issues.
13. Act in accordance with the ethical, legal and philosophical principles and values of the genetic counseling profession and the practice of such institutions or organizations.
14. Advocate for individuals, families, communities and the genetic counseling profession.
15. Demonstrate a self-reflective, evidence-based and critical approach to genetic counseling practice.
16. Understand the research, roles and history of the profession of clinical genetic counseling.
17. Establish and maintain professional relationships and networking.

Genomics...?



## ACGC Competencies 2015

### Domain I: Genetics Expertise and Analysis

1. Demonstrate and utilize a depth and breadth of understanding and knowledge of *genetics* and *genomics* core concepts and principles.
2. Integrate knowledge of psychosocial aspects of conditions with a genetic component to promote *client* well-being.
3. Construct relevant, targeted and comprehensive personal and family histories and pedigrees.
4. Identify, assess, facilitate, and integrate genetic testing options in genetic counseling practice.
5. Assess individuals' and their relatives' *probability of conditions with a genetic component* or carrier status based on their pedigree, test result(s), and other pertinent information.
6. Demonstrate the skills necessary to successfully manage a genetic counseling case.
7. Critically assess genetic/genomic, medical and social science literature and information.

